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Peripheral bloodmononuclear cells (PBMCs) were collected from a clinically diagnosed 20-year-old dystonia pa-
tient with a GCH1mutation (DYT5). Episomal vectors were used to introduce reprogramming factors (OCT3/4,
SOX2, KLF4, L-MYC, LIN28, and p53 carboxy-terminal dominant-negative fragment) to the PBMCs. The generated
iPSCs expressed pluripotency markers, and were capable of differentiating into derivates of all three germ layers
in vitro. The iPSC line also showed a normal karyotype and preserved theGCH1mutation. This cellular model can
provide opportunities to perform pathophysiological studies for aberrant dopamine metabolism-related
disorders.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Resource table.












Type of cell line iPSC
Origin Human
Additional origin info Age: 20-year-old
Sex: male




















RIKEN BioResource Center, Japan
http://en.brc.riken.jp/index.shtml
Ethical approval The Ethics Committee of the Department of Medicine and
Graduate School of Medicine, Kyoto University (R0091
and G259) and Tokushima University (3172 and H26-9)
Resource utility
Research investigating dystonia using patient-derived iPSCs is limit-
ed, and a single nucleotide polymorphism in GCH1 is reportedly associ-
ated with Parkinson's disease. This finding has the potential to provide
new insight into not only DYT5 but also Parkinson's disease.
Resource details
Autosomal dominantGTP cyclohydrolase I (GCH1) deficiency,which
is characterized by dopa-responsive dystonia with marked diurnal fluc-
tuations, was first reported in 1976 by Segawa et al. (1976). GCH1 is in-
volved in the production of tetrahydrobiopterin (BH4), which is an
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essential cofactor for biosynthesis of dopamine. Heterozygous GCH1
mutation leads to partial deficiency of BH4 and selective decreases of ty-
rosine hydroxylase in nigrostriatal dopamine neurons, which causes
dopa-responsive dystonia (Segawa et al., 2003), alternatively called as
Segawa disease or DYT5. A large-scale genome-wide association study
meta-analysis also revealed that a single nucleotide polymorphism at
GCH1 is associated with Parkinson's disease (Nalls et al., 2014). Periph-
eral blood mononuclear cells (PBMCs) derived from a 20-year-old dys-
tonia patient with a GCH1mutation c.626+1GNC were reprogrammed
by inducing episomal vectors with OCT3/4, SOX2, KLF4, L-MYC, LIN28,
and p53 carboxy-terminal dominant-negative fragment, as previously
reported (Okita et al., 2013) (Fig. 1A). The generated iPSCs expressed
pluripotency markers, including NANOG and SSEA4 (Fig. 1B) and were
capable of differentiating into derivates of all three germ layers, namely,
endoderm (SOX-17), mesoderm (αSMA), and ectoderm (βIII-tubulin)
(Fig. 1C). Short tandem repeat (STR) analysis of the iPSC line was iden-
tical to the parental PBMCs (Supplementary Table 1). The iPSC line had a
normal karyotype (46 XY) (Fig. 1D). The reprogramming process did
not alter a GCH1mutation, as demonstrated in Fig. 1E. By flow cytome-
try, 66.1% of iPSCs were positive for SSEA4 (Fig. 1F). Collectively, the




Generation and use of human iPSCs was approved by the Ethics
Committee of theDepartment ofMedicine andGraduate School ofMed-
icine, Kyoto University, and Tokushima University. All methods were
Fig. 1. Characterization of iPSC line. (A) The DYT5 patient iPSCs displayed a typical round-shaped colony under microscopy. Scale bar: 200 μm (B) Immunocytochemical staining of iPSCs
showed high expression of pluripotencymarker NANOG and SSEA4. Scale bars: 200 μm. (C) Pluripotency of iPSCs was confirmed by in vitro three-germ layer assay. Scale bars: 50 μm. (D)
Karyotype analysis of patient iPSCs showed a normal karyotype of 46 XY. (E) Sanger sequence of the GCH1 gene in iPSCs showed a heterozygous c.626+1GNC substitution. (F) FACS
analysis with evaluation of SSEA-4 staining.
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performed in accordance with approved guidelines. Formal informed
consent was obtained from the patient.
Generation of iPSCs
Human complementary DNAs for reprogramming factors were
transduced in PBMCs with episomal vectors (OCT3/4, SOX2, KLF4, L-
MYC, LIN28 and p53 carboxy-terminal dominant-negative fragment).
The generated iPSCs were grown under feeder-free conditions on lami-
nin-511 E8 (Nippi, Tokyo, Japan)-coated plates with StemFit (AK02N or
AK03N, Ajinomoto, Tokyo, Japan) (Nakagawa et al., 2014) (Table 1).
Karyotyping and genotyping of GCH1
Karyotype analysis was performed by LSI Medience (Tokyo, Japan).
Genotyping of the GCH1mutation was performed by PCR amplification
of genomic DNA and direct sequencing (3500xL Genetic Analyzer, Ap-
plied Biosystems, Waltham, MA) (Table 2).
In vitro three-germ layer assay
iPSCs were dissociated with 0.5× TrypLE Select (Gibco, Waltham,
MA) and used for embryoid body (EB) formation. Cells were transferred
to suspension plates in Dulbecco's modified Eagle's medium/Ham's F12
(DMEM/F12, Sigma-Aldrich, St. Louis, MO) containing 20% knockout
serum replacement (KSR, Life Technologies, Waltham, MA), 2 mM L-
glutamine, 0.1 mM non-essential amino acids (NEAA, Invitrogen, Wal-
tham, MA), 0.1 mM 2-mercaptoethanol (2-ME, Life Technologies), and
0.5% penicillin and streptomycin. On Day 8, EBs were seeded onto gela-
tin-coated plates, and cultivated for 8 days.
Immunocytochemical staining
Cells were fixed in 4% paraformaldehyde in PBS for 20 min at room
temperature, washed three times with PBS after each step, and blocked
with 5% bovine serum albumin for 1 h at room temperature followed by
incubation with primary antibodies at 4 °C overnight. The primary anti-
bodies used for staining are listed in Table 2. Suitable secondary anti-
bodies were incubated at room temperature for 1 h. Nuclear staining
was also performed with DAPI for 5 min. Images were collected using
BIOREVO BZ-9000 (Keyence, Osaka, Japan) or Olympus CKX41 (Olym-
pus, Tokyo, Japan) (Tables 1 and 2).
Flow cytometry analysis
iPSCs were dissociated into single cells using Accumax (Innovative
Cell Technologies, SanDiego, CA) andwere incubated at 1.0 × 106 cells/-
ml in PBS with 2% FBS and 20 μl SSEA4 APC conjugated monoclonal an-
tibody (BD Biosciences, Franklin Lakes, NJ) for 30 min at 4 °C. After
staining, the cells were washed twice in PBS with 2% FBS, and then
stored in PBS with 2% FBS on ice. Cells were analyzed on a FACS Aria II
(BD Biosciences) high-speed cell sorter using a 647 nm excitation
Table 2
Summary of antibodies and primers.
Antibodies used for immunocytochemistry/flow cytometry
Antibody Dilution Company Cat# and RRID
Pluripotency markers Rabbit anti-NANOG 1:500 Cosmo Bio Co Cat# REC-RCAB0003P, RRID: AB_1962353
Pluripotency markers Mouse anti-SSEA4 1:1000 Millipore Cat# MAB4304, RRID: AB_177629
Differentiation markers Goat anti-SOX-17 1:1000 R and D Systems Cat# AF1924, RRID: AB_355060
Differentiation markers Mouse anti-αSMA 1:500 Dako Cat# M0851, RRID: AB_2223500
Differentiation markers Rabbit anti-βIII-tubulin 1:2000 Cell Signaling Technology Cat# 5568P, RRID: AB_10692510
Secondary antibodies Donkey anti-Goat IgG Alexa Fluor 488 1:1000 Thermo Fisher Scientific Cat# A-11055, RRID: AB_142672
Secondary antibodies Goat anti-Rabbit IgG Alexa Fluor 488 1:1000 Thermo Fisher Scientific Cat# A-11034, RRID: AB_2576217
Secondary antibodies Goat anti-Mouse IgG Alexa Fluor 546 1:1000 Thermo Fisher Scientific Cat# A-11030, RRID: AB_2534089
Secondary antibodies Goat anti-Rabbit IgG Alexa Fluor 546 1:1,000 Thermo Fisher Scientific Cat# A-11010, RRID: AB_10584649
Primers
Target Forward/reverse primer (5′-3′)
Genotyping GCH1 exon 1 CAGGTGCAGCAATGGGTTCC/CGCACTGACCTGAGATGGTCTCC
Genotyping GCH1 exon 2 TTCTCCTTCCTCTTCCATACTGC/TGAGAGCCTTCTGCTACTTTGG
Genotyping GCH1 exon 3 CCGCATTTACCAACGGACAAC/CAGGTAAAGAGAGAAAGCCTGATG
Genotyping GCH1 exon 4 TTCCTCTTGCAGCCCACTTGCTTC/CACAGTGGCTCATGCCTGTAATCC
Genotyping GCH1 exon 5 GGGCTTCAGGGTGTTCTGAGA/AGCTTTAGGCTCAGGGATGG
Genotyping GCH1 exon 6 ACTTGGTAACTGTGAGCTGAG/GGTGGCAAGAAGAAAGTAGAGG
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Visual record of the line: normal Fig. 1 panel A
Phenotype Immunocytochemistry Assess staining of pluripotency markers: NANOG and SSEA4 Fig. 1 panel B
Flow cytometry SSEA4 66.1% Fig. 1 panel F
Genotype Karyotype (G-banding) and resolution 46XY
Resolution 300–400
Fig. 1 panel D
Identity Microsatellite PCR (mPCR) Not performed Not performed
STR analysis 16 loci, matched Supplementary Table 1
Mutation analysis (IF
APPLICABLE)
Sequencing Heterozygous c.626+1GNC mutation Fig. 1 panel E
Southern Blot OR WGS Not performed Not performed
Microbiology and
virology
Mycoplasma Contamination of Mycoplasma was negative Not shown but available
from author
Differentiation potential Embryoid body formation OR Teratoma
formation OR Scorecard
Describe expression of genes in embryoid bodies: SOX-17, αSMA,
and βIII-tubulin
Fig. 1 panel C
Donor screening HIV 1+2 Hepatitis B, Hepatitis C HIV1 (negative), HIV2 (not performed), Hepatitis B (negative), and
Hepatitis C (negative)
Not shown but available
from author
Genotype additional info Blood group genotyping Not performed Not performed
HLA tissue typing Not performed Not performed
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wavelength and 100 μm nozzle. Unstained cells were also analyzed as
negative controls to exclude data from non-specific fluorescence.
DNA fingerprinting
STR analysis was performed by BEX (Tokyo, Japan) from PBMCs and
the iPSC line.
Mycoplasma test
iPSCs were confirmed to be mycoplasma-negative using the
MycoAlert kit (Lonza, Basel, Switzerland) in accordance with the
manufacturer's instructions.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2017.07.029.
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